Navigation Links
Hologic, Inc. Announces Grant of Early Termination of Antitrust Waiting Period for Third Wave Technologies, Inc. Tender Offer
Date:6/25/2008

BEDFORD, Mass., June 25 /PRNewswire-FirstCall/ -- Hologic, Inc. (Nasdaq: HOLX) today announced that the Federal Trade Commission granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the "HSR Act"), on June 24, 2008, in connection with Hologic's previously announced tender offer for all of the outstanding shares of the common stock of Third Wave Technologies, Inc. (Nasdaq: TWTI). The early termination of the waiting period under the HSR Act satisfies the conditions to the tender offer related to the expiration or termination of any applicable waiting periods under the HSR Act and other state and foreign regulatory laws relating to the restraint of trade or lessening of competition. The tender offer remains subject to certain other conditions described in the Offer to Purchase.

As previously announced, Hologic commenced a Tender Offer on June 18, 2008 for all of the outstanding shares of Third Wave common stock for $11.25 per share in cash. The tender offer is scheduled to expire at 12:00 midnight, New York City time, on July 16, 2008.

About Hologic, Inc.

Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostics, medical imaging systems and surgical products dedicated to serving the healthcare needs of women. Hologic's core business units are focused on breast health, diagnostics, GYN surgical, and skeletal health. Hologic provides a comprehensive suite of technologies with products for mammography and breast biopsy, radiation treatment for early-stage breast cancer, cervical cancer screening, treatment for menorrhagia, osteoporosis assessment, preterm birth risk assessment, and mini C-arm for extremity imaging. For more information visit http://www.hologic.com.

Additional Information

This description contained herein is neither an offer to purchase nor a solicitation of an offer to sell shares of Third Wave. The tender offer is being made pursuant to a Tender Offer Statement and related materials. Third Wave shareholders are advised to read the Tender Offer Statement and related materials filed by Hologic with the U.S. Securities and Exchange Commission (the "SEC"). At the time the tender offer commenced, Hologic and Thunder Tech Corp. (a wholly- owned subsidiary of Hologic) filed a Tender Offer Statement on Schedule TO containing an Offer to Purchase, the form of the letter of transmittal and other documents relating to the tender offer, and Third Wave filed a Solicitation/Recommendation Statement on Schedule 14D-9 with respect to the tender offer. These documents contain important information about the tender offer, including the terms and conditions of the tender offer, and shareholders of Third Wave are urged to read them carefully. Shareholders of Third Wave are able to obtain a free copy of these documents at http://www.hologic.com and the website maintained by the SEC at http://www.sec.gov. In addition, shareholders are able to obtain a free copy of these documents by contacting Hologic or Third Wave.

Contact:

Glenn P. Muir

Executive Vice President & CFO

Hologic, Inc.

(781) 999-7300

Frances Doria

Director, Investor Relations

Hologic, Inc.

(781) 999-7377


'/>"/>
SOURCE Hologic, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Hologic, Inc. to Host Investor Reception at the RSNA Trade Show
2. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
3. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
4. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
5. HEI, Inc. Announces Sale of RFID Division Assets
6. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
7. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
8. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
9. Brooke Franchise Corporation Announces Selected July Results
10. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
11. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... ... , ... "I have gout, and I wanted to treat it naturally," said ... to relieve gout and pain caused by varicose veins. I drank it every morning ... relieved what VA doctors called the worst sinusitis case they'd seen and relieved gas, ...
(Date:12/9/2016)... ... December 09, 2016 , ... The Holy Name Medical Center ... NY, on December 3rd, to benefit Holy Name Medical Center's programs and services. ... raised over $1 million - the largest event in the Center's history, both ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... by the Undersea and Hyperbaric Medical Society (UHMS), the leading authority in hyperbaric ... patient safety. Only a few hospitals and facilities have earned this distinction. This ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... Therapy Management (MTM), adherence, and other pharmacist-delivered patient care services, has announced the ... and Eric Hoessel to vice president of sales. , Litsinger joined Mirixa ...
(Date:12/8/2016)... ... 08, 2016 , ... SunView Software aims to redefine IT ... both engaging and easy to use. Coming off the heels of a successful ... its plans to roll out new AI-powered self-service enhancements to help organizations implement ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... 9, 2016 Research and Markets has ... report to their offering. ... The report forecasts the global optical transceiver market ... The report covers the present scenario and the ... calculate the market size, the report considers the revenue generated from ...
(Date:12/9/2016)... aTyr Pharma, Inc. (Nasdaq: LIFE ), a biotherapeutics company ... severe, rare diseases, today announced that senior management will participate in ... Conference at the InterContinental Barclay Hotel in New York ... ET. About aTyr Pharma ... aTyr Pharma is engaged in the ...
(Date:12/9/2016)... Bermuda , Dec. 9, 2016  Axovant ... leading clinical-stage biopharmaceutical company focused on the treatment ... the data from a Phase 2b trial evaluating ... care donepezil, compared with donepezil plus placebo in ... that the addition of intepirdine to treatment was ...
Breaking Medicine Technology: